Cdk2 suppresses cellular senescence induced by the c-myc oncogene (original) (raw)

• Campisi, J. & d'Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nature Rev. Mol. Cell Biol. 8, 729–740 (2007).
  Article CAS Google Scholar
• Schmitt, C. A. Cellular senescence and cancer treatment. Biochim. Biophys. Acta (2006).
• Amati, B., Alevizopoulos, K. & Vlach, J. Myc and the cell cycle. Front. Biosci. 3, D250–D268 (1998).
  Article CAS Google Scholar
• Ortega, S. et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nature Genet. 35, 25–31 (2003).
  Article CAS Google Scholar
• Berthet, C., Aleem, E., Coppola, V., Tessarollo, L. & Kaldis, P. Cdk2 knockout mice are viable. Curr. Biol. 13, 1775–1785 (2003).
  Article CAS Google Scholar
• Parrinello, S. et al. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nature Cell Biol. 5, 741–747 (2003).
  Article CAS Google Scholar
• Grandori, C. et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 17, 1569–1574 (2003).
  Article CAS Google Scholar
• Robinson, K., Asawachaicharn, N., Galloway, D. A. & Grandori, C. c-Myc accelerates S-Phase and requires WRN to avoid replication stress. PLoS One 4, e5951 (2009).
  Article Google Scholar
• Santamaria, D. et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811–815 (2007).
  Article CAS Google Scholar
• Martin, A. et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7, 591–598 (2005).
  Article CAS Google Scholar
• Aleem, E., Kiyokawa, H. & Kaldis, P. Cdc2–cyclin E complexes regulate the G1/S. phase transition. Nature Cell Biol. 7, 831–836 (2005).
  Article CAS Google Scholar
• Satyanarayana, A., Hilton, M. B. & Kaldis, P. p21 inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S. phase DNA damage checkpoint. Mol. Biol. Cell (2007).
• Deb-Basu, D., Karlsson, A., Li, Q., Dang, C. V. & Felsher, D. W. MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2. Cell Cycle 5, 1348–1355 (2006).
  Article CAS Google Scholar
• Felsher, D. W., Zetterberg, A., Zhu, J., Tlsty, T. & Bishop, J. M. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc. Natl Acad. Sci. USA 97, 10544–10548 (2000).
  Article CAS Google Scholar
• Deb-Basu, D., Aleem, E., Kaldis, P. & Felsher, D. W. CDK2 is required by MYC to induce apoptosis. Cell Cycle 5, 1342–1347 (2006).
  Article CAS Google Scholar
• Pelengaris, S., Khan, M. & Evan, G. I. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321–334 (2002).
  Article CAS Google Scholar
• Vafa, O. et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9, 1031–1044 (2002).
  Article CAS Google Scholar
• Pusapati, R. V. et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc. Natl Acad. Sci. USA 103, 1446–1451 (2006).
  Article CAS Google Scholar
• Shreeram, S. et al. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J. Exp. Med. 203, 2793–2799 (2006).
  Article CAS Google Scholar
• Gorrini, C. et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448, 1063–1067 (2007).
  Article CAS Google Scholar
• Reimann, M. et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood (2007).
• Maclean, K. H., Kastan, M. B. & Cleveland, J. L. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol. Cancer Res. 5, 705–711 (2007).
  Article CAS Google Scholar
• Dominguez-Sola, D. et al. Non-transcriptional control of DNA replication by c-Myc. Nature 448, 445–451 (2007).
  Article CAS Google Scholar
• Louis, S. F. et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc. Natl Acad. Sci. USA 102, 9613–9618 (2005).
  Article CAS Google Scholar
• Gao, P. et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12, 230–238 (2007).
  Article CAS Google Scholar
• Deans, A. J. et al. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res. 66, 8219–8226 (2006).
  Article CAS Google Scholar
• Woo, R. A. & Poon, R. Y. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev. 18, 1317–1330 (2004).
  Article CAS Google Scholar
• Ray, S. et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 66, 6598–6605 (2006).
  Article CAS Google Scholar
• Nilsson, J. A. et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7, 433–444 (2005).
  Article CAS Google Scholar
• Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A. & Berns, A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413, 83–86 (2001).
  Article CAS Google Scholar
• Martins, C. P. & Berns, A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J. 21, 3739–3748 (2002).
  Article CAS Google Scholar
• Macias, E., Kim, Y., Miliani de Marval, P. L., Klein-Szanto, A. & Rodriguez-Puebla, M. L. Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. Cancer Res. 67, 9713–9720 (2007).
  Article CAS Google Scholar
• Feldser, D. M. & Greider, C. W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461–469 (2007).
  Article CAS Google Scholar
• Cosme-Blanco, W. et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 8, 497–503 (2007).
  Article CAS Google Scholar
• Tetsu, O. & McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3, 233–245 (2003).
  Article CAS Google Scholar
• Sugimoto, K. et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79, 2378–2383 (1992).
  CAS PubMed Google Scholar
• Chi, Y. et al. Identification of CDK2 substrates in human cell lysates. Genome Biol. 9, R149 (2008).
  Article Google Scholar
• Matsuura, I. et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430, 226–231 (2004).
  Article CAS Google Scholar
• Alevizopoulos, K., Vlach, J., Hennecke, S. & Amati, B. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated Retinoblastoma-family proteins. EMBO J. 16, 5322–5333 (1997).
  Article CAS Google Scholar
• Vlach, J., Hennecke, S., Alevizopoulos, K., Conti, D. & Amati, B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 15, 6595–6604 (1996).
  Article CAS Google Scholar
• Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002).
  Article CAS Google Scholar
• Wu, C. H. et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl Acad. Sci. USA (2007).
• Goga, A., Yang, D., Tward, A. D., Morgan, D. O. & Bishop, J. M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nature Med. 13, 820–827 (2007).
  Article CAS Google Scholar
• Morgenstern, J. P. & Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587–3596 (1990).
  Article CAS Google Scholar
• Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G. & Evan, G. I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23, 1686–1690 (1995).
  Article CAS Google Scholar
• Hemann, M. T. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807–811 (2005).
  Article CAS Google Scholar
• Fanidi, A., Harrington, E. A. & Evan, G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359, 554–556 (1992).
  Article CAS Google Scholar
• Bahram, F., Wu, S., Oberg, F., Luscher, B. & Larsson, L. G. Posttranslational regulation of Myc function in response to phorbol ester/interferon-γ-induced differentiation of v-Myc-transformed U-937 monoblasts. Blood 93, 3900–3912 (1999).
  CAS PubMed Google Scholar
• Brooks, E. E. et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272, 29207–29211 (1997).
  Article CAS Google Scholar
• Murga, M. et al. Global chromatin compaction limits the strength of the DNA damage response. J. Cell Biol. 178, 1101–1108 (2007).
  Article CAS Google Scholar
• Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985).
  Article CAS Google Scholar
• Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289–298 (2002).
  Article CAS Google Scholar
• Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
  Article CAS Google Scholar